Premium
MOSUNETUZUMAB MONOTHERAPY IN ELDERLY/UNFIT PTS WITH FIRST‐LINE DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): SAFETY AND EFFICACY REMAIN PROMISING WITH DURABLE COMPLETE RESPONSES
Author(s) -
Olszewski A. J,
Avigdor A,
Babu S,
Levi I,
Eradat H,
Abadi U,
Holmes H,
McKinney M,
Woszczyk D,
Giannopoulos K,
Jurczak W,
McCord R,
Xie Y,
Sarouei K,
Qayum N,
O'Hear C,
Sellam G,
Horowitz N
Publication year - 2021
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.152_2880
Subject(s) - medicine , bendamustine , tolerability , diffuse large b cell lymphoma , rituximab , gastroenterology , adverse effect , chemoimmunotherapy , neutropenia , oncology , surgery , lymphoma , toxicity